Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01398501
First received: July 19, 2011
Last updated: February 11, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)